Literature DB >> 21999156

Limitations of Hb F as a phenotypic modifier in sickle cell disease: study of Kuwaiti Arab patients.

Adekunle D Adekile1.   

Abstract

Sickle cell disease is characterized by phenotypic heterogeneity and many genetic modifiers have been identified with elevated Hb F being the most recognized ameliorating factor. Kuwaiti sickle cell disease patients carry the India/Arab chromosomal haplotype, which is associated with elevated Hb F (on average ~22%) on account of the Xmn1 site in the (G)γ-globin gene promoter. Most patients had either Hb SS or Hb S-β(0)-thalassemia (β(0)-thal) and there are a few Hb SD compound heterozygotes. We have carried out longitudinal clinical studies of these patients to document the pattern of morbidity, spleen function, brain and hip magnetic resonance imaging (MRI) for prevalence of silent brain infarcts and avascular necrosis of the femoral head (AVNFH), respectively. In addition, pulmonary function, SPECT (single photon emission computerized tomography) brain cerebral blood flow and response of selected patients to hydroxyurea (HU) treatment were also studied. The Hb SS and Hb S-β-thal patients have a generally mild phenotype compared to sickle cell disease in other populations and most patients do not have their first pain crisis until about the age of 4 years. Spleen function is retained till late childhood; pneumococcemia and other severe bacterial infections are rare. Overt stroke and silent brain infarcts are uncommon in childhood (~3% prevalence) although SPECT reveals cerebral blood flow deficits in ~30%. Avascular necrosis of the femoral head is, however, common with a prevalence of ~26% in children and 50% in adults. There is brisk response to HU in patients with frequent pain crises, with marked increases in Hb F levels. Patients who are compound heterozygotes for Hbs S and D-Los Angeles, have the most severe phenotype despite Hb F levels of >20% and Hb S <30%. In conclusion, although the patients have a uniformly elevated Hb F level, there are still considerable phenotypic heterogeneity and other modulating genetic factors that require further studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21999156     DOI: 10.3109/03630269.2011.617230

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  9 in total

Review 1.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 2.  Intravascular hemolysis and the pathophysiology of sickle cell disease.

Authors:  Gregory J Kato; Martin H Steinberg; Mark T Gladwin
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

3.  Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype.

Authors:  Duyen Ngo; Harold Bae; Martin H Steinberg; Paola Sebastiani; Nadia Solovieff; Clinton T Baldwin; Efthymia Melista; Surinder Safaya; Lindsay A Farrer; Ahmed M Al-Suliman; Waleed H Albuali; Muneer H Al Bagshi; Zaki Naserullah; Idowu Akinsheye; Patrick Gallagher; Hong-yuan Luo; David H K Chui; John J Farrell; Amein K Al-Ali; Abdulrahman Alsultan
Journal:  Blood Cells Mol Dis       Date:  2013-03-07       Impact factor: 3.039

4.  Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign.

Authors:  Abdulrahman Alsultan; Mohammed K Alabdulaali; Paula J Griffin; Ahmed M Alsuliman; Hazem A Ghabbour; Paola Sebastiani; Waleed H Albuali; Amein K Al-Ali; David H K Chui; Martin H Steinberg
Journal:  Br J Haematol       Date:  2013-11-13       Impact factor: 6.998

Review 5.  A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.

Authors:  Gift D Pule; Shaheen Mowla; Nicolas Novitzky; Charles S Wiysonge; Ambroise Wonkam
Journal:  Expert Rev Hematol       Date:  2015-09-01       Impact factor: 2.819

Review 6.  An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.

Authors:  Khuthala Mnika; Gift D Pule; Collet Dandara; Ambroise Wonkam
Journal:  OMICS       Date:  2016-09-16

Review 7.  The Genetic and Clinical Significance of Fetal Hemoglobin Expression in Sickle Cell Disease.

Authors:  Adekunle Adekile
Journal:  Med Princ Pract       Date:  2020-09-04       Impact factor: 1.927

8.  Is sickle cell disease the same everywhere?

Authors:  Jane Hankins
Journal:  Rev Bras Hematol Hemoter       Date:  2012

9.  Morbidity pattern in hospitalized under five children with sickle cell disease.

Authors:  Dipty Jain; A S Bagul; Maulik Shah; Vijaya Sarathi
Journal:  Indian J Med Res       Date:  2013-09       Impact factor: 2.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.